Aripiprazole-d8 is intended for use as an internal standard for the quantification of aripiprazole by GC- or LC-MS. Aripiprazole is an atypical antipsychotic.1 It is a partial agonist at dopamine D2, D2L, and D3 receptors (Kis = 3.3, 0.74, 9.7 nM, respectively), a partial agonist of the serotonin (5-HT) receptor subtype 5-HT1A (Ki = 5.6 nM), and an inverse agonist of 5-HT2B receptors (Ki = 0.36 nM). It is functionally selective at the dopamine D2 receptor with cell-type- and function-selective activities. Aripiprazole inhibits disruptions in prepulse inhibition induced by phencyclidine in mice when administered at doses of 5 and 10 mg/kg.2 Formulations containing aripiprazole have been used in the treatment of schizophrenia, bipolar mania or mixed episodes, and Tourette’s disorder.
1.Shapiro, D.A., Renock, S., Arrington, E., et al.Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacologyNeuropsychopharmacology28(8)1400-1411(2003) 2.Fejgin, K., Safonov, S., P?lsson, E., et al.The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in micePsychopharmacology (Berl.)191(2)377-385(2007)